Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
06/2003
06/26/2003WO2003051342A1 Compressed oral pharmaceutical dosage form, with an enteric coating, which contains an acid-labile benzimidazole compound
06/26/2003WO2003051341A1 Dosage form for providing time-varying patterns of drug delivery
06/26/2003WO2003051340A1 New film coating
06/26/2003WO2003051339A1 Release control type formed product
06/26/2003WO2003051338A1 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
06/26/2003WO2003051337A1 Pre-formulation for the tabletting of natural mixtures of conjugated estrogens
06/26/2003WO2003051336A1 Matrix film tablets for the controlled release of natural mixtures of conjugated estrogen
06/26/2003WO2003051335A1 Radioopaque sustained release pharmaceutical system
06/26/2003WO2003051334A2 Pharmaceutical composition comprising an oil/water/oil double microemulsion incorporated into a solid support
06/26/2003WO2003051333A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/26/2003WO2003051332A1 Ophthalmic compositions comprising two different polyanionic components for lubricating eyes and methods for making and using same
06/26/2003WO2003051330A1 Solid dosage form for the ocular administration of an active principle, a soluble, solid ophthalmic insert and the production method thereof
06/26/2003WO2003051329A1 Agent for oral administration and method for producing the same
06/26/2003WO2003051328A1 Solid dose micro implant
06/26/2003WO2003051304A2 Bioadhesive drug delivery system with enhanced gastric retention
06/26/2003WO2003051300A2 Metal complexes and formulations of rifamycin analogues and uses therof
06/26/2003WO2003051299A2 Sulfhydryl rifamycins and uses thereof
06/26/2003WO2003051294A2 Mitocidal compositions and methods
06/26/2003WO2003051293A2 Antidiabetic formulation and method
06/26/2003WO2003051288A2 Mycobacterial vaccine
06/26/2003WO2003051287A2 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003WO2003051286A2 Hydrogel compositions, devices, and microscale components
06/26/2003WO2003051281A2 Composition and method to treat viral bacterial and parasitic infections and infestations
06/26/2003WO2003051278A2 Nanoparticle delivery vehicle
06/26/2003WO2003051273A2 Dermal cholic acid as anti-inflammatory and theraputic agent
06/26/2003WO2003051114A1 Shelf life extension of microemulsions containing active aza biocide
06/26/2003WO2003032896A3 Dexibuprofen-containing soft gelatin capsules and process for preparing the same
06/26/2003WO2003030920A9 An antispasmodic agent spaced drug delivery system
06/26/2003WO2003026612A3 Dosage forms having an inner core and outer shell
06/26/2003WO2003026610A3 Process for the preparation of fast dissolving dosage form
06/26/2003WO2002098352A3 PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
06/26/2003WO2002065834A8 Novel formulations of carvedilol
06/26/2003WO2002062404A3 Closure of ruptured tissue and bulking of tissue
06/26/2003WO2001097778A8 Amphotericin b structured emulsion
06/26/2003US20030120262 Implantable infusion pump with level measurement
06/26/2003US20030120224 Feminine care products for the delivery of therapeutic substances
06/26/2003US20030120204 Oxygen delivery agents and uses for the same
06/26/2003US20030120059 Cell surface molecule-induced macrophage activation
06/26/2003US20030119956 An oil in water emulsion comprising an alkaline to increase the solubility of aza compound; control infestations, infections of livestock or domestic animals; topical application, veterinary medicine
06/26/2003US20030119916 Treatment of functional gastrointestinal disorders
06/26/2003US20030119911 Levothyroxine sodium and liothyronine sodium in solid form with microcrystalline cellulose; treating hypothyroidism and thyroid hormone replacement therapy
06/26/2003US20030119906 Pharmaceutical forms for the oral administration of mesna
06/26/2003US20030119901 Phenylene ethers with a benzamidine group; leukotriene b4 (ltb4)
06/26/2003US20030119893 Non-selective beta-blocker with a vasodilating component
06/26/2003US20030119883 Crystalline material
06/26/2003US20030119879 Nicotine replacement therapy including tobacco substitution and smoking cessation; rapid transmucosal absorption of nicotine; oral and nasal drug delivery; rapid absorption; bioavailability; taste-masking; dosage; Alzheimer's
06/26/2003US20030119872 Process for preparing non-hygroscopic sodium valproate composition
06/26/2003US20030119859 Useful in the prophylaxis and treatment of respiratory diseases
06/26/2003US20030119841 Treatment and prevention of anxiety and convulsive disorders
06/26/2003US20030119812 Administering a staurosporine derivative, especially N-benzoylstaurosporine, or salt thereof
06/26/2003US20030119802 Use particularly in the prophylaxis and treatment of respiratory diseases.
06/26/2003US20030119801 Stabilized tibolone compositions
06/26/2003US20030119797 Methods for selective immunomodulation
06/26/2003US20030119794 Also containing an acetylsalicylate anionand a beta-receptor blocker or a hypertensive agent; especially treating cardiac arrest, angina and shock
06/26/2003US20030119783 Aqueous compositions containing metronidazole
06/26/2003US20030119781 Hyaluronic acid in soft gel form
06/26/2003US20030119768 Reducing toxicity by treating the oligonucleotide in multimeric aggregate form to convert all of it to a monomeric form and to prevent the formation of aggregates before administration
06/26/2003US20030119760 Water insoluble polymer, such as ethyl cellulose; and an optimizing agent, such as a Eudragit acrylic polymer, optionally containing lactose, dicalcium phosphate and/or tricalcium phosphate
06/26/2003US20030119728 Stable, nasally, orally or sublingually applicable pharmaceutical preparation
06/26/2003US20030119727 FVIIa antagonists
06/26/2003US20030119718 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
06/26/2003US20030118988 Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
06/26/2003US20030118691 Masticatory for treating gastroesophageal reflux disease; a chewing-gum base and an acid neutralizing agent and/or an acid production inhibitor
06/26/2003US20030118672 Administering a stabilized rice bran derivative and a fortification agent; treating bone disorders
06/26/2003US20030118669 Novel substituted benzimidazole dosage forms and method of using same
06/26/2003US20030118660 Residual solvent extraction method and microparticles produced thereby
06/26/2003US20030118657 Treatment of disease states characterized by excessive or inappropriate angiogenesis
06/26/2003US20030118656 Controlled release formulation of divalproex sodium
06/26/2003US20030118655 Film forming liquid composition
06/26/2003US20030118654 Taste masked aqueous liquid pharmaceutical composition
06/26/2003US20030118653 An inner layer disposed between two moisture barrier coatings, comprising a water soluble hydrocolloid and an active material; multilayer, protective coatings, sustained release, controlled release
06/26/2003US20030118652 Methods and compositions for use of (S)-bisoprolol
06/26/2003US20030118651 Active material is cationic when the carrier is anionic, active material is anionic when the carrier is cationic; active agent is ionically linked to the carrier, transdermal by contacting the tissue surface
06/26/2003US20030118650 Tableted oral pharmaceutical dosage form, with enteric coating, containing a compound of benzimidazole labile in an acid medium
06/26/2003US20030118649 Sustained release of bioactive agent, comprising a central core, layer coatings, each containing bioactive agent
06/26/2003US20030118648 Two combined tablet portions, with different releasing rates; drug delivery providing immediate, sustained and prolonged release
06/26/2003US20030118647 Extended release tablet of metformin
06/26/2003US20030118646 Enantiomers, drug for the treatment of narcolepsy, hypotension, attention-deficit hyperactivity disorder
06/26/2003US20030118645 Pharmaceutical compositions for rectal and vaginal administration
06/26/2003US20030118644 A solid forms comprising low molecular weight peptide-based thrombin inhibitor having pH dependent solubility, cellulose or starch as disintegrant fillers; immediate release
06/26/2003US20030118643 Preparing a fast-dissolving drug mixture from difficultly soluble active material, 70% dissolution rate, from an aqueous suspension containing the active substance and water-soluble adjuvants, dehydrating
06/26/2003US20030118642 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
06/26/2003US20030118641 Abuse-resistant sustained-release opioid formulation
06/26/2003US20030118640 Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate
06/26/2003US20030118639 Controlled release pharmaceutical composition
06/26/2003US20030118638 Oral pharmaceutical products containing 17 beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation
06/26/2003US20030118637 Preventing antibody-induced anemia by administering a complexes of bisphosphonate
06/26/2003US20030118636 Delivery of small hydrophilic molecules packaged into lipid vesicles
06/26/2003US20030118633 Treating unstable or overactive urinary bladder by administering an antimuscarinic agent and an estrogen agonist
06/26/2003US20030118632 Methods and compositions for treating carpal tunnel syndrome
06/26/2003US20030118630 Immune modulation device for use in animals
06/26/2003US20030118629 Water-in-oil emulsions with anionic groups, compositions, and methods
06/26/2003US20030118623 Composition based on etyl ester of linoleic acid and triethyl ester of citric acid for topical use in the treatment of seborrhea and acne
06/26/2003US20030118613 Compositions having improved delivery of actives
06/26/2003US20030118610 Oral delivery of peptides using enzyme-cleavable membrane translocators
06/26/2003US20030118598 Botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising botulinum toxin and recombinant albumin, suitable for therapeutic administration to humans
06/26/2003US20030118594 Stable formulations of mhc-peptide complexes
06/26/2003US20030118581 Adsorbent for oral administration
06/26/2003US20030118558 Lysin-deficient bacteriophages having reduced immunogenicity
06/26/2003US20030118553 Vector constructs for gene-therapy mediated radionuclide therapy of undifferentiated and medullary thyroid carcinomas and non-thyroidal tumours and metastases mediated thereof
1 ... 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 ... 2991